Surmodics Inc (NASDAQ:SRDX) 2017 Q3 Institutional Investor Sentiment Steady

January 22, 2018 - By Maria Brooks

 Surmodics Inc (NASDAQ:SRDX)  2017 Q3 Institutional Investor Sentiment Steady

Sentiment for Surmodics Inc (NASDAQ:SRDX)

Surmodics Inc (NASDAQ:SRDX) institutional sentiment decreased to 0.94 in 2017 Q3. Its down -0.06, from 1 in 2017Q2. The ratio is negative, as 45 funds started new and increased stock positions, while 48 cut down and sold their stakes in Surmodics Inc. The funds in our partner’s database now hold: 11.18 million shares, down from 11.19 million shares in 2017Q2. Also, the number of funds holding Surmodics Inc in their top 10 stock positions was flat from 1 to 1 for the same number . Sold All: 5 Reduced: 43 Increased: 30 New Position: 15.

Surmodics, Inc., together with its subsidiaries, provides surface modification and in vitro diagnostic technologies to the healthcare industry worldwide. The company has market cap of $381.83 million. It operates through two divisions, Medical Device and In Vitro Diagnostics. It has a 100.52 P/E ratio. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.

The stock decreased 1.19% or $0.35 during the last trading session, reaching $29.15. About 14,755 shares traded. Surmodics, Inc. (NASDAQ:SRDX) has risen 6.57% since January 22, 2017 and is uptrending. It has underperformed by 10.13% the S&P500.

Analysts await Surmodics, Inc. (NASDAQ:SRDX) to report earnings on February, 1. They expect $-0.05 earnings per share, down 126.32 % or $0.24 from last year’s $0.19 per share. After $0.18 actual earnings per share reported by Surmodics, Inc. for the previous quarter, Wall Street now forecasts -127.78 % negative EPS growth.

Trigran Investments Inc. holds 8.97% of its portfolio in Surmodics, Inc. for 1.28 million shares. Murphy Pohlad Asset Management Llc owns 64,200 shares or 1.38% of their US portfolio. Moreover, Teton Advisors Inc. has 0.8% invested in the company for 276,792 shares. The California-based Menta Capital Llc has invested 0.27% in the stock. Rice Hall James & Associates Llc, a California-based fund reported 109,631 shares.#img1#

Since January 1, 0001, it had 0 insider purchases, and 4 selling transactions for $208,525 activity.

Surmodics, Inc. (NASDAQ:SRDX) Ratings Coverage

Ratings analysis reveals 50% of SurModics’s analysts are positive. Out of 4 Wall Street analysts rating SurModics, 2 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $29 while the high is $43.5. The stock’s average target of $37.50 is 28.64% above today’s ($29.15) share price. SRDX was included in 5 notes of analysts from August 6, 2015. On Friday, October 7 the stock rating was downgraded by Sidoti to “Neutral”. As per Thursday, August 6, the company rating was maintained by Barrington Research. The company was downgraded on Monday, November 21 by Barrington Research.

More news for Surmodics, Inc. (NASDAQ:SRDX) were recently published by: Nasdaq.com, which released: “Surmodics (SRDX) Poised on Core Business Amid Forex Woes” on January 11, 2018. Businesswire.com‘s article titled: “Surmodics Receives 510(K) Clearance for Telemarkâ„¢ Coronary/Peripheral Support …” and published on January 22, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.